glp 1 gpi Medication Options for Type 2 Diabetes it helps increase faecal bulk for digestive comfort Potential Use of GLP-1 and

Discontinue Byetta if pancreatitis is suspected Notes: The discovery of DPP-IV-resitant GLP-1 analogs was pursued in parallel with the discovery of DPP-IV inhibitors

In the absence of sponsor-validated stability data, the following general principles apply to reconstituted injectable peptides in UK aseptic practice (as reflected in NHS Specialist Pharmacy Service guidance on aseptically prepared products): Reconstituted solutions prepared outside a licensed aseptic unit carry a higher risk of microbial contamination and chemical degradation Beyond-use dates must be assigned based on validated data, not on analogy with other products If no validated beyond-use date is available, the product should be used immediately or discarded It is important to note that antimicrobial preservatives in a diluent do not guarantee chemical stability of the peptide itself

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies

Basal insulin and cardiovascular and other outcomes in dysglycemia